SCHEMBL19134337

SCHEMBL19134337

CC(C)C(C)CCN1CCCC1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.56
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
PKM P14618 1/20 0.46
LMNA P02545 3/20 0.43
BRD4 O60885 1/20 0.42
BRD2 P25440 1/20 0.42
TSHR P16473 3/20 0.42
CHRM2 P08172 3/20 0.40
CHRM5 P08912 3/20 0.40
CHRM1 P11229 3/20 0.40
CHRM3 P20309 3/20 0.40
CYP2D6 P10635 2/20 0.40
ALDH1A1 P00352 2/20 0.40
APEX1 P27695 2/20 0.40
PMP22 Q01453 2/20 0.40
ALOX12 P18054 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3430972 0.85 PIK3CD (0.66) PIK3CDKMT2AMEN1PKMLMNA
SCHEMBL7649491 0.83 PIK3CD (0.58) PIK3CDKMT2AMEN1PKMLMNA
SCHEMBL20886713 0.81 PIK3CD (0.56) PIK3CDKMT2AMEN1PKMLMNA
SCHEMBL22004101 0.81 PIK3CD (0.51) PIK3CDKMT2AMEN1PKMLMNA
SCHEMBL21207378 0.80 PIK3CD (0.55) PIK3CDKMT2AMEN1PKMLMNA
SCHEMBL12197894 0.79 PIK3CD (0.58) PIK3CDKMT2AMEN1PKMLMNA
SCHEMBL22600522 0.79 PIK3CD (0.53) PIK3CDKMT2AMEN1PKMLMNA
SCHEMBL1705435 0.79 PIK3CD (0.53) PIK3CDKMT2AMEN1PKMLMNA
SCHEMBL22021621 0.79 PIK3CD (0.53) PIK3CDKMT2AMEN1PKMLMNA
SCHEMBL104477 0.78 PIK3CD (0.61) PIK3CDKMT2AMEN1PKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020102616-A1 ACLY INHIBITORS AND USES THEREOF Nimbus Artemis, Inc. (US) 2020-05-22 WO disclosed
US-9708337-B2 Aryl amide-based kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-07-18 US disclosed